BASF’s Personal Care business is launching a new synthetic peptide for skin care applications. Inspired by the natural regenerative process of the skin, Pepsensyal (INCI: Mannitol (and) Acetyl shTetrapeptide-1 (and) Lauroyl sh-Tetrapeptide-1) has been clinically proven to reduce and delay the first visible signs of aging.
The new ingredient is a response to the slow-aging trend, which reflects a shift in consumer attitudes: Rather than fighting the natural aging process, consumers are increasingly concerned with healthy aging through a holistic, preventative approach to skin care.
In recent years, peptides in particular have gained a lot of traction in the personal care market and are recognized by consumers as effective, science-backed ingredients. Pepsensyal expands BASF's peptide portfolio with a new cost-effective variant. The new ingredient is free of preservatives and 99% of natural origin.
Clinically proven triple action for slow aging: smoothing, resurfacing, redensifying
In a double-blind, randomized, split-face clinical trial with 32 women aged between 44 and 64, Pepsensyal at 0.2% was tested against a placebo product without the new ingredient. After only 14 days, crow's feet appeared smoother, with an 11% decrease in average roughness and a 14% decrease in maximum relief amplitude.
At the same time, skin isotropy increased by 15%, indicating a skin resurfacing effect. In that same test, Pepsensyal was also proven to replenish the skin from the inside: After 28 days, the skin had re-densified, with a 21% increase in the echogenic surface area of the dermis. Extensive in vitro testing has confirmed the ingredient's ability to support skin regeneration, helping to slow the visible signs of skin aging.
Pepsensyal is just one recent example of how the company’s Care Chemicals division is addressing future challenges. Sustainability, digitalization, innovation and new approaches to working together are the key cornerstones to Care 360° – Solutions for Sustainable Life.
Fibre2Fashion News Desk (HU)